Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
about
Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cellsTherapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signalingA role for FACT in repopulation of nucleosomes at inducible genesRepurposing the anti-malarial drug, quinacrine: new anti-colitis propertiesDiscovery of a Carbazole-Derived Lead Drug for Human African TrypanosomiasisFACT is a sensor of DNA torsional stress in eukaryotic cells.Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells.CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response.Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemiaCuraxins: a new family of non-genotoxic multitargeted anticancer agents.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismQuinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerCuraxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.Small-molecule xenomycins inhibit all stages of the Plasmodium life cycleExpression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells.Recent progress in targeting cancer.Quantitative interactome analysis reveals a chemoresistant edgotype.Protective effect of quinacrine against glycerol-induced acute kidney injury in rats.Biological clues to potent DNA-damaging activities in food and flavoring.Histone chaperone FACT action during transcription through chromatin by RNA polymerase IISSRP1 Contributes to the Malignancy of Hepatocellular Carcinoma and Is Negatively Regulated by miR-497ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.Regulation of Replication Fork Advance and Stability by Nucleosome Assembly.Modulation of chromatin structure by the FACT histone chaperone complex regulates HIV-1 integration.Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.p53 and the Carcinogenicity of Chronic Inflammation.A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cellsInhibition of the FACT Complex Reduces Transcription from the Human Cytomegalovirus Major Immediate Early Promoter in Models of Lytic and Latent Replication."Naked" FACT is unstable.Stabilization of Nucleosomes by Histone Tails and by FACT Revealed by spFRET Microscopy.Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical ModelsFACT in Cell Differentiation and Carcinogenesis.Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation.Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.Zebrafish as a model to study neuroblastoma development.TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells.
P2860
Q27702290-0CB4C567-4893-46AF-91E7-64ACDFD73CA3Q27853237-57AF8CC5-912D-49DB-8332-EFF3E0CFA17BQ28483751-0446F127-5C47-4EE6-A363-3DDCD3A77D70Q28538271-FBD9BC10-EE83-4A55-999D-A3CBD3E4E560Q28817699-F8DBF916-1E5D-4C9B-9B1A-33561B617FC8Q28828834-8F39EC81-E2BE-4AC8-9402-38840A04ACF7Q33557785-DFB57D2E-8BA8-43C7-875B-CCE992718E7FQ33591234-7655482E-974F-4453-A4BA-7F117C6960C0Q33688623-3B894D31-5F4D-46AA-AD58-C0FC4B4ADA69Q33767881-B8709FB8-DE55-4829-8FB0-1BA2A29B2627Q34061949-C5D10560-76F7-431F-AF1C-5673A0B83F14Q34079481-511C1B23-3A9E-43E3-A3FD-32C0ACB088B3Q34143354-EE508D84-B4AF-406D-999C-DF225AAE88E6Q34957154-BD6B30DD-8E08-4F4E-911D-B9B6D69781CFQ35076935-174C55C4-ABA0-4F2D-9941-1DB15F77D23FQ35640168-9AA92CA6-A5F7-496B-BAEB-B2B3AF1B79C8Q35740782-17B1DBFF-C90B-475B-8BFC-905ED3B70BB4Q35941833-11EF9FF2-5D07-4286-B5ED-7D222D5AF3CBQ36262805-2838979C-64D3-41B5-B690-C79168DC2397Q36717985-0E6E3431-064C-4E65-B2BE-EC1A610DE58AQ36835414-DB8D1B65-0D27-484C-8552-A43A4BE6BE38Q36939787-585FB5D4-B066-4955-8F52-109910879777Q37091948-C2B07BA2-1810-4348-8E6B-7CE4333219B2Q37676224-A441B787-AEF6-4CE7-AF59-3B0A6BDDEAC7Q38654758-3CCFCAAC-7E34-4830-A13F-EB723C6494B1Q38744639-6C2EB623-B3C7-4A2A-9D24-F26E4611DD6CQ38934157-ADFA0EE2-43A0-4538-ABB1-106339A71422Q39033771-DD566049-8546-4934-9300-747DC5643E59Q39128319-368C2CBB-414A-44D8-80FE-27DDE2F06363Q39599295-84A966E0-22D1-4260-88C3-E4DE23CB8C56Q41909628-3CD3E378-1F30-4814-A09C-EE362D2E6625Q42138478-CF9E4EF1-F32D-4871-B280-A826F73181E8Q42359768-3E1B4054-64F4-47C5-A08B-05708D0D685DQ42775850-950737E0-73F7-4874-B963-CDF87A5EC033Q43057166-60B082C9-78F3-4F52-B8B1-3F6DDF2A38EFQ43376660-265DDBC6-16FC-4373-8C06-48DA29B19291Q47201695-CFCF884B-3348-4771-AE1E-32D8C390CA5AQ47877975-9AC6B723-38C8-4767-A1EF-2C0B69C0D685Q47899604-AEF55464-5625-40CB-BFE4-4DF133AB358BQ48106178-E263C535-284A-4906-B51E-3460280CBB15
P2860
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Curaxins: anticancer compounds ...... ctivate p53 by targeting FACT.
@en
Curaxins: anticancer compounds ...... ctivate p53 by targeting FACT.
@nl
type
label
Curaxins: anticancer compounds ...... ctivate p53 by targeting FACT.
@en
Curaxins: anticancer compounds ...... ctivate p53 by targeting FACT.
@nl
prefLabel
Curaxins: anticancer compounds ...... ctivate p53 by targeting FACT.
@en
Curaxins: anticancer compounds ...... ctivate p53 by targeting FACT.
@nl
P2093
P2860
P1476
Curaxins: anticancer compounds ...... activate p53 by targeting FACT
@en
P2093
Alexander V Gasparian
Alfiya Safina
Andrei A Purmal
Andrei V Gudkov
Catherine A Burkhart
Dmitry A Bosykh
Igor E Koman
Jean Veith
Katerina V Gurova
Leonid Brodsky
P2860
P304
P356
10.1126/SCITRANSLMED.3002530
P407
P50
P577
2011-08-01T00:00:00Z